Story
Hims & Hers Stock Gains After FDA Panel Recommends Wider Access for BPC-157 Peptide

Shares of Hims & Hers Health, Inc. (NYSE: HIMS) rose sharply on Tuesday after a U.S. Food and Drug Administration (FDA) advisory panel narrowly recommended expanding consumer access to the peptide BPC-157. The development was viewed favorably by the market, given the telehealth company's focus on wellness and prescription products.
Panel Delivers Narrow Recommendation
According to a report from Investing.com, the stock climbed 7.9% following the announcement. The move was a direct reaction to the FDA advisory committee's vote on the compound.
Key details from the vote include:
- A final tally of 8-to-6 in favor of the recommendation.
- One committee member abstained from the vote.
AdThe outcome represents a potentially positive step for companies like Hims & Hers that operate in the health and wellness space and could offer products containing the peptide.
A Non-Binding but Important Step
It is crucial for investors to understand that recommendations from FDA advisory committees are non-binding. The FDA will consider the panel's input but is not obligated to follow its guidance when making a final regulatory decision.
The close vote margin suggests a significant division of opinion among the experts on the panel regarding the peptide's safety and efficacy for wider availability. The FDA will now weigh this divided recommendation as it determines the final regulatory pathway for BPC-157.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.